Robert C. Scott

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott et al. · New England Journal of Medicine · 2015 · 1.5K citations · Full text

Heart Failure, Lipid Peroxidation, Hyperlipidemia +19

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

Stephen J. Nicholls, Rishi Puri, Todd J. Anderson et al. · JAMA · 2016 · 1.1K citations · Full text

On The Direction of Preference for Moments of Higher Order Than The Variance

Robert C. Scott, Philip A. Horvath · The Journal of Finance · 1980 · 744 citations

Engineering, Asset Pricing, Probability Theory +3

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 734 citations

Metabolic Syndrome, Lipid Disorder, Heterozygous Familial Hypercholesterolaemia +11

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Narimon Honarpour, Dirk Blom et al. · The Lancet · 2014 · 720 citations

Metabolic Syndrome, Lipid Disorder, Homozygous Familial Hypercholesterolaemia +11